新诊断转移性肾细胞癌患者的延迟性减瘤性肾切除术
基于IMDC数据库(2006-2018)分析1541例新诊断mRCC患者,比较单用舒尼替尼、先行减瘤性肾切除术(CN)后舒尼替尼、舒尼替尼后延迟CN(dCN)的结局。dCN组中位OS达46个月,显著优于单用舒尼替尼(10个月)和先CN组(19个月);多变量分析显示dCN与改善OS和TTF独立相关。
要点
- 舒尼替尼后延迟CN与单用舒尼替尼相比,OS显著改善(HR=0.45)。
- 延迟CN组中位OS为46个月,先CN组19个月,单用舒尼替尼组10个月。
- dCN患者经过严格选择,其长期生存获益需前瞻性试验确认。
核心结论
- 接受延迟性减瘤性肾切除术的患者经过仔细选择,获得了较长的总生存期。
- 需要确定最佳选择标准,并通过临床试验确认dCN的作用。
研究设计与样本
- 研究使用前瞻性维护的国际mRCC数据库联盟(IMDC)数据库,纳入2006-2018年新诊断mRCC患者。
- 共评估1541例患者:651例(42%)单用舒尼替尼,805例(52%)先行CN后舒尼替尼,85例(5.5%)舒尼替尼后dCN(中位时间7.8个月)。
- 采用Kaplan-Meier和多变量Cox回归分析,dCN作为时变协变量以校正不朽时间偏倚。
主要发现
- 单用舒尼替尼、先CN后舒尼替尼、舒尼替尼后dCN的中位OS分别为10、19、46个月。
- 上述三组的中位TTF分别为4、8、13个月。
- 多变量分析中,与单用舒尼替尼相比,舒尼替尼后dCN显著改善OS(HR=0.45,95%CI 0.33-0.60,p<0.001)和TTF(HR=0.62,95%CI 0.46-0.85,p=0.003)。
- 在CN治疗患者中,与先CN后舒尼替尼相比,舒尼替尼后dCN显著改善OS(HR=0.52,95%CI 0.39-0.70,p<0.001)和TTF(HR=0.71,95%CI 0.56-0.90,p=0.005)。
- 多种敏感性分析中,dCN仍与改善OS和TTF显著相关。
临床怎么用
- 对于新诊断mRCC患者,可考虑先给予舒尼替尼等系统治疗,根据反应选择合适患者进行延迟性减瘤性肾切除术。
- 延迟CN可能为经过选择的患者带来显著生存获益,但需注意患者选择偏倚。
局限性
- dCN患者经过仔细选择,可能存在选择偏倚。
- 研究为回顾性数据库分析,dCN的作用需前瞻性临床试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of cytoreductive nephrectomy (CN) selectively for patients who show a favorable response to upfront systemic therapy may be an approach to select optimal candidates with metastatic renal cell carcinoma (mRCC) who are most likely to benefit. OBJECTIVE: We sought to characterize outcomes of deferred CN (dCN) after upfront sunitinib, outcomes relative to sunitinib alone, and outcomes of CN followed by sunitinib. DESIGN, SETTING, AND PARTICIPANTS: We used the prospectively maintained International mRCC Database Consortium (IMDC) database to identify patients with newly diagnosed mRCC (2006-2018). INTERVENTION: Sunitinib alone, upfront CN followed by sunitinib, sunitinib followed by dCN. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Outcomes were overall survival (OS) and time to sunitinib treatment failure (TTF). Kaplan-Meier and multivariable Cox regression analyses were performed; dCN was analyzed as a time-varying covariate to account for immortal time bias. RESULTS AND LIMITATIONS: We evaluated 1541 patients, of whom 651 (42%) received sunitinib alone, 805 (52%) underwent CN followed by sunitinib, and 85 (5.5%) received sunitinib followed by dCN, at a median of 7.8 mo from diagnosis. Median OS periods for patients treated with sunitinib alone, CN followed by sunitinib, and sunitinib followed by dCN were 10, 19, and 46 mo, respectively, while the median TTF values were 4, 8, and 13 mo, respectively. In multivariable regression analyses, sunitinib followed by dCN was significantly associated with improved OS (hazard ratio [HR] = 0.45, 95% confidence interval [CI] 0.33-0.60, p < 0.001) and TTF (HR = 0.62, 95% CI 0.46-0.85, p = 0.003) versus sunitinib alone. Among CN-treated patients, sunitinib followed by dCN was associated with improved OS (HR = 0.52, 95% CI 0.39-0.70, p < 0.001) and TTF (HR = 0.71, 95% CI 0.56-0.90, p = 0.005) compared with upfront CN followed by sunitinib. In various sensitivity analyses, dCN remained significantly associated with improved OS and TTF. CONCLUSIONS: Patients who received dCN were carefully selected and achieved long OS. With these benchmark outcomes, optimal selection criteria need to be identified and confirmation of the role of dCN in a clinical trial is warranted. PATIENT SUMMARY: We characterized benchmark survival outcomes for patients with metastatic kidney cancer treated with sunitinib alone, nephrectomy (kidney removal) followed by sunitinib, and sunitinib followed by nephrectomy. Patients who had their nephrectomy after an initial course of sunitinib had prolonged survival.
引用
- Bhindi B, Graham J, Wells JC, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. 2020. PMID: 32362493. doi:10.1016/j.eururo.2020.04.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。